Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Pituitary
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Pituitary
    New Technology Provides Safe and Effective Means of Performing Minimally Invasive Pituitary Surgery: Presented at AAO-HNSF - (DGDispatch)
    Investigative Pasireotide Suppresses Growth Hormone in Acromegaly Without Affecting Glucose Tolerance: Presented at AACE - (DGDispatch)
    Daily Thyroxine Dose Up to 1.4 mcg/kg Not Adequate in Hypopituitary Patients: Presented at ECE - (DGDispatch)
    Endoscopic Pituitary Surgery Effective and Safe as the Primary Treatment for Acromegaly: Presented at ECE - (DGDispatch)
    Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review - (JAMA)

    News archive

     Recent webcasts/CME - Pituitary
      Diagnosis and Management of Pituitary Adenomas

      Webcasts/CME archive

       Recent cases - Pituitary
        Effects of Growth Hormone Reduction in a Patient with Polycystic Ovary Syndrome Complicated with Acromegaly
        Management of Pituitary Adenoma with Mass Effect in Pregnancy: A Case Report
        Mandibular Prognathism Caused By Acromegaly - A Surgical Orthodontic Case
        Deficiency of Growth Hormone in an Adult Man Case of Idiopathic Adrenocorticotropin Deficiency
        Polycystic Ovary Syndrome and Prolactinoma Association

        Cases archive
          




        my personal edition > pituitary > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Evaluation of Serum Test to Screen for Secondary Adrenal Insufficiency: Presented at AACE

        By Maggie Schwarz

        WASHINGTON, DC -- May 27, 2005 -- A 25 mcg cosyntropin stimulation test is both accurate and convenient for evaluating the hypothalamic-pituitary-adrenal (HPA) axis, according to new research.

        "We've been using a screening test for secondary adrenal insufficiency that's more accurate than traditional tests," said Ali Usmani, MD, a third-year resident in internal medicine at the Cleveland Clinic Health System in Cleveland, Ohio, United States.

        Dr. Usmani said he and his associates were seeking a good screening test because the 1 and 250 mcg cosyntropin stimulation tests are unreliable. They've been using a 25 mcg test for 2 years, evaluated it, and announced its level of diagnostic accuracy here May 19th at the American Association of Clinical Endocrinologists (AACE) 14th Annual Meeting and Clinical Congress.

        In their study, 43 patients underwent the cosyntropin stimulation test and either an insulin tolerance test (n = 26) or metyrapone test (n = 17). Twenty controls underwent measurement of their serum cortisol level before and at 30 and 60 minutes after administration of cosyntropin.

        In patients who underwent a pituitary surgical procedure, all tests were performed at least 4 weeks postoperatively. Most (31 of 43) of the patients had a pituitary macroadenoma. Magnetic resonance imaging of the pituitary showed normal findings in 14 patients and a microadenoma in six.

        A cortisol cutoff value of 18.0 mcg/dL at 30 minutes resulted in the best combination of sensitivity and specificity, at 88.9% and 59.5%, respectively. Of the 27 patients who failed the insulin tolerance test or metapyrone test, three passed the 25 mcg cosyntropin stimulation test. Two of these three patients did not benefit from glucocorticoid therapy, which was subsequently discontinued without sequelae.

        "Though the specificity of 59.5% isn't that impressive, it's acceptable for a screening test," explained Dr. Usmani. "If the test comes out negative, there's an 88.9% chance the patient does not have secondary adrenal insufficiency. If the test comes out positive, the patient is then referred for insulin tolerance testing or the metapyrone test, if the patient is not a candidate for insulin tolerance testing."

        Secondary adrenal insufficiency is a result of pituitary dysfunction. "It's an important diagnosis to catch," said Dr. Usmani, "since it can be the cause of malaise, fatigue, weight problems, and depression. Secondary adrenal insufficiency can be fatal in cases of stress, shock, or surgery because the body doesn't produce enough adrenal hormone."


        [Presentation title: Hypothalamic-Pituitary-Adrenal Axis Testing With Use of a 25-mcg Cosyntropin Stimulation Test. AACE: 896.]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send